| DIA | SEMANA | MÊS | 3 MESES | 6 MESES | 12 MESES | NO ANO |
|---|---|---|---|---|---|---|
| 0,00% | +2,93% | +2,93% | +13,77% | +30,11% | +49,08% | +20,37% |
| DIA | SEMANA | MÊS | 3 MESES | 6 MESES | 12 MESES | NO ANO | |
|---|---|---|---|---|---|---|---|
| BIIB34 | 0,00% | +2,93% | +2,93% | +13,77% | +30,11% | +49,08% | +20,37% |
| IBOV | −1,06% | −0,92% | +9,56% | +17,55% | +3,81% | +43,28% | +26,81% |
| CDI | 0,00% | +0,15% | +1,02% | +3,25% | +6,71% | +14,30% | +11,01% |
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etan…